IMS: Focalin has $19 million in annual sales.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has received final approval from the US Food and Drug Administration (FDA) to market its generic version of Novartis' Focalin (Dexmethylphenidate Hydrochloride) Tablets, 2.5 mg, 5 mg, and 10 mg.
Focalin is indicated for the treatment of attention deficit hyperactivity disorder. The brand product had annual sales of approximately $19 million for the twelve months ended September 2006, based on IMS sales data.
Teva added that it was currently in patent litigation concerning this product in the US District Court for the District of New Jersey.
The latest approval represents further good news for Teva, whose stock has produced a return of 13.6% since the beginning of 2007, after being classed as the stock with the poorest rate of return on the Tel Aviv 25 Index.
Published by Globes [online], Israel business news - www.globes.co.il - on January 30, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007